Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1569912 in Major Depressive Disorder
NCT06558344Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BI 1569912 in major depressive disorder (MDD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Oct 2024; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06558344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558344.